Latest

Latest antibody News | Page 2

  • Latest antibody news stories and updates. What is happening today? All recent antibody news and developments. Live coverage and timeline of antibody. All you need to know about antibody.
World-first breakthrough in malaria treatment
La Trobe University and AdAlta collaboration delivers world-first breakthrough in malaria treatment
FDA grants fast-track designation for EnGeneIC’s pancreatic cancer candidate
Statement on the antigen composition of COVID-19 vaccines
Being overweight hampers immune response to SARS-CoV-2
AstraZeneca advances scientific leadership in haematology at ASH 2023
Social network of proteins
Telix says first patient dosed in ProstACT study of prostate cancer candidate
9M and Q3 2023 results
Imugene announces phase 1 clinical trial opens with onCARlytics CD19 virus technology
Arovella Therapeutics licences monoclonal antibody for cell therapy development
New treatment offers hope for advanced liver cancer
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01…
Imugene secures new patent in Japan for PD1-Vaxx clinical drug candidate
Enhertu demonstrated strong and durable tumour responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Phase II trial
Advanced Technology Reveals Intricate Details of Zinc Transportation in Cells
Does picking your nose really increase your risk of COVID?
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial
Mater midwife’s life-saving gift to thousands of mothers
Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
Update on brazikumab development programme
Making Vaccines Longer Lasting
Radiopharm Theranostics and GenesisCare partner on development of radiopharmaceutical
Novel Regulatory Mechanism of Blood Clotting Discovered
Patrys’ says preclinical data supports synthetic lethality mechanism
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial
CSL reports positive results from pivotal late-stage trial of first-in-class garadacimab
TGA provisionally approves Moderna’s new bivalent Covid vaccine
TGA grants provisional approval to Moderna’s COVID-19 bivalent (SPIKEVAX Bivalent Original/Omicron BA.4-5) booster dose vaccine
TGA grants provisional approval to Pfizer’s COVID-19 bivalent (COMIRNATY Original/Omicron BA.4-5 COVID-19 vaccine) booster dose vaccine
WHO updates COVID-19 guidelines on masks, treatments and patient care
Exploring air we breathe
Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive
Anatomical barriers shield brain from SARS-CoV-2 invasion at vulnerable interfaces
Enhertu achieved statistically significant overall survival, reducing risk of death by 36% vs. trastuzumab emtansine
Australian venture capital fund joins partners in backing new immunotherapy
AstraZeneca aims to redefine breast cancer care with new data across treatment spectrum at SABCS 2022
CSL and Translational Sciences enter Agreement
Dr Michelle Boyle named 2023 CSL Centenary Fellow
NATURE publishes data on DUNP19 receptors role in cancer growth
Live Intracellular Imaging with New, Conditionally Active Immunofluorescence Probe
Enhertu continues to demonstrate clinically meaningful tumour response
TGA provisionally approves Moderna bivalent Covid vaccine for use as booster dose in adults
CSL starts planning to submit new antibody treatment
CSL Announces Positive Results for Garadacimab
Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial vs. physician’s choice of treatment
Enhertu approved in US as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell

© 2025 - The National Tribune Australia